Recommend the creation of a Chief Patient Officer.
Read more
Provide input on pharmacare.
Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.
Discuss Canada's response to the proposed bulk importation of medications from Canada to the United States.
Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.
Share patient groups perspectives on drug pricing and access to medications/vaccines/clinical trials, specifically regulations and guidelines related to the Patented Medicine Prices Review Board, along with feedback on their policies and practices, and processes related to PMPRB.
Provide input on a national strategy for drugs for rare diseases.
Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.
Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.
Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.
Support input into the consultation on draft guidance on decentralized clinical trials.
Recommend the creation of a Patient Ombudsman.
Support input regarding Canada’s pharmaceutical sovereignty.
Support input into the consultation on Canada Gazette, Part I, Volume 159, Number 51: Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.